Atopic dermatitis, also known as atopic eczema, is a condition that results in itchy, scaly and red skin. It is an inflammatory skin disease which is a common recurrent form of skin allergy.
Acute flare-ups of eczematous pruritic lesions mainly categorise atopic dermatitis over dry skin due to high levels of immunoglobulin E (IgE).
As already discussed in our one of the previous articles, our immune system releases histamines in response to allergens. However, with the term Atopic associated with the form of allergies, shows the genetic disposition of developing the disease. In layman terms, Atopic dermatitis patients pool, in general, have determined genetic risk factors which affect the skin barriers. However, genetic factors are not the only factors that cause the manifestation of the disease. Research suggests that there exist environmental triggers that initiate the allergy. Factors like low humidity, seasonal allergies, harsh soaps, detergents and cold weather can also trigger Atopic dermatitis. Early manifestations of the disease appear in early life and keep on recurring. Furthermore, Atopic dermatitis often precedes other allergic disorders such as asthma and allergic rhinitis, can be a progression of Atopic march, including atopic dermatitis (eczema), food allergy, allergic rhinitis (hay fever) and asthma.
Atopic dermatitis Epidemiology
Atopic dermatitis is not contagious. It is a common form of skin disease in both adults and children, with 10-20 % of the total global populations suffering from Atopic dermatitis at some point in their lives.
Atopic dermatitis prevalence, however, commonly affects up to 20% of the children and around 3% of the adults, is increasing, especially in low-income countries.
DelveInsight analysts revealed that total Atopic dermatitis prevalent population in 7MM was estimated to be around 41,261,411 in 2017. Moreover, a higher Atopic dermatitis prevalence is observed in the United States approximately 19,460,609 cases, when compared with other geographies in 7MM, i.e., EU5 countries and Japan.
Atopic dermatitis Treatment Market
Atopic dermatitis treatment market mainly constitutes of controlling measures rather than preventive cures.
Topical therapies are the mainstay in Atopic dermatitis treatment market.
Topical corticosteroids are considered the first line of treatment of Pruritus in Atopic dermatitis treatment market and occupy the maximum share.
Other therapies like immunosuppressants, antihistamines, and topical calcineurin inhibitors such as tacrolimus and pimecrolimus also have a place in Atopic dermatitis market and reduce inflammation and itching. Tacrolimus and Pimecrolimus are expensive, non-steroid topical ointments. They hamper the production of a substance known as calcineurin which is responsible for inflammation.
Phototherapy is another form of therapy present in Atopic dermatitis market used to treat both localised and concentrated forms of eczema. Also known as Light therapy, it reduces itch, mild infection down, increases Vitamin D concentration and upgrades the ability of the immune system to fight bacteria.
Atopic dermatitis Market
Atopic dermatitis market analysis by DelveInsight revealed that the total market size in 7 MM was estimated to be around USD 2422 Million in 2017. Furthermore, Atopic dermatitis market size, as calculated in the US, was observed to be around USD 1038 Million. Market Size of Atopic Dermatitis was estimated to be 1038 USD Millions in 2017 in the United States.
Atopic dermatitis treatment market is majorly dominated by the use of corticosteroids, immunosuppressants, and calcineurin inhibitors.
Atopic dermatitis market is further driven by approved therapies such as Eucrisa (Pfizer) and Dupilumab (Regeneron Pharmaceuticals/Sanofi).
Approved in 2017, Dupilumab developed by Regeneron Pharmaceuticals, is a first biologic that has been approved for treating AD patients by effectively in reducing inflammation via inhibition of cytokines-Interleukin 4 and Interleukin 13.
Atopic dermatitis pipeline
Key pharma players such as Galderma Pharma, LEO Pharma, Roviant Sciences, and many others are involved in fueling Atopic dermatitis market.
Expected launch of emerging therapies such as Nemolizumab (Galderma Pharma), and Tralokinumab (LEO Pharma), Tradipitant (Vanda Pharmaceuticals), Etrasimod (Arena Pharmaceuticals) and other treatments are expected to change the Atopic Dermatitis treatment landscape in upcoming years.
Companies like Kaken Pharmaceuticals, Valent Pharmaceutical, Astellas Pharma, Meda AB, Valeant and others are also developing novel therapies to add value to the Atopic dermatitis market. However, Kaken Pharmaceuticals has stopped mid-stage trials of its topical drug KP-413 ointment is without any further notice. Atopic dermatitis market has significant unmet needs such as uncertain causes of indication, prevalence as a symptom, and preventive treatment methods. Several pieces of research conducted suggest that Atopic dermatitis is instead a consequence of other several allergic diseases and is one of the concomitant diseases.
Overall, a robust pipeline filled with novel therapies along with the rising prevalence of the disease will lead to a significant boost to the market revenue generated during the forecast period [2019-2028].